Timing of therapies for Down syndrome: the sooner, the better.
Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public health. Accumulating evidence shows that DS is characterized by numerous neurodevelopmental alterations among which the reduction of neurogenesis, dendritic hypotrophy and connectivity alterations appear to play a particularly prominent role. Although the mechanisms whereby gene triplication impairs brain development in DS have not been fully clarified, it is theoretically possible to correct trisomy-dependent defects with targeted pharmacotherapies. This review summarizes what we know about the effects of pharmacotherapies during different life stages in mouse models of DS. Since brain alterations in DS start to be present prenatally, the prenatal period represents an optimum window of opportunity for therapeutic interventions. Importantly, recent studies clearly show that treatment during the prenatal period can rescue overall brain development and behavior and that this effect outlasts treatment cessation. Although late therapies are unlikely to exert drastic changes in the brain, they may have an impact on the hippocampus, a brain region where neurogenesis continues throughout life. Indeed, treatment at adult life stages improves or even rescues hippocampal neurogenesis and connectivity and hippocampal-dependent learning and memory, although the duration of these effects still remains, in the majority of cases, a matter of investigation. The exciting discovery that trisomy-linked brain abnormalities can be prevented with early interventions gives us reason to believe that treatments during pregnancy may rescue brain development in fetuses with DS. For this reason we deem it extremely important to expedite the discovery of additional therapies practicable in humans in order to identify the best treatment/s in terms of efficacy and paucity of side effects. Prompt achievement of this goal is the big challenge for the scientific community of researchers interested in DS.
Department of Biomedical and Neuromotor Sciences, University of Bologna Bologna, Italy.
Fiorenza
F
Stagni
Department of Biomedical and Neuromotor Sciences, University of Bologna Bologna, Italy.
Andrea
A
Giacomini
Department of Biomedical and Neuromotor Sciences, University of Bologna Bologna, Italy.
Sandra
S
Guidi
Department of Biomedical and Neuromotor Sciences, University of Bologna Bologna, Italy.
Elisabetta
E
Ciani
Department of Biomedical and Neuromotor Sciences, University of Bologna Bologna, Italy.
Renata
R
Bartesaghi
Down syndrome; adult therapies; intellectual disability; mouse models; perinatal therapies